$SRAX
SRAX, Inc. Stock $srax

$srax Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000149315224037704 Filed on September 20, 2024

Income Statement

Concept	2024 Q3	2022 Q4	2022
Revenue			$27.86M
YoY Change			4.31%
Cost Of Revenue			$9.413M
YoY Change			44.35%
Gross Profit			$18.45M
YoY Change			-8.62%
Gross Profit Margin			66.21%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization			$417.0K
YoY Change			479.17%
% of Gross Profit			2.26%
Operating Expenses
YoY Change
Operating Profit			$4.003M
YoY Change			-4809.41%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net			-$35.64M
YoY Change			119.88%
Pretax Income			-$31.64M
YoY Change			94.17%
Income Tax
% Of Pretax Income
Net Earnings			-$31.64M
YoY Change			-8.99%
Net Earnings / Revenue			-113.56%
Basic Earnings Per Share			-$1.21
Diluted Earnings Per Share			-$1.21
COMMON SHARES
Basic Shares Outstanding	29.15M shares	26.32M shares	26.25M shares
Diluted Shares Outstanding			26.25M shares

Balance Sheet

Concept	2024 Q3	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments		$9.193M
YoY Change		-0.18%
Cash & Equivalents		$7.000K
Short-Term Investments		$9.186M
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables		$157.0K
Other Receivables
Total Short-Term Assets		$8.853M
YoY Change		-61.48%
LONG-TERM ASSETS
Property, Plant & Equipment		$59.00K
YoY Change		-48.25%
Goodwill		$7.706M
YoY Change		-56.96%
Intangibles		$0.00
YoY Change		-100.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$9.217M
YoY Change		-55.45%
TOTAL ASSETS
Total Short-Term Assets		$8.853M
Total Long-Term Assets		$9.217M
Total Assets		$18.07M
YoY Change		-58.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$7.476M
YoY Change		82.56%
Accrued Expenses		$2.540M
YoY Change		67.33%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$21.72M
YoY Change		-4.81%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$5.600M
YoY Change		4812.28%
TOTAL LIABILITIES
Total Short-Term Liabilities		$21.72M
Total Long-Term Liabilities		$5.600M
Total Liabilities		$27.32M
YoY Change		19.14%
SHAREHOLDERS EQUITY
Retained Earnings		-$61.99M
YoY Change		104.23%
Common Stock		$26.00K
YoY Change		-99.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$9.249M
YoY Change
Total Liabilities & Shareholders Equity		$18.07M
YoY Change		-58.63%

Cashflow Statement

Concept	2024 Q3	2022 Q4	2022
OPERATING ACTIVITIES
Net Income			-$31.64M
YoY Change			-8.99%
Depreciation, Depletion And Amortization			$417.0K
YoY Change			479.17%
Cash From Operating Activities			-$12.33M
YoY Change			-47.4%
INVESTING ACTIVITIES
Capital Expenditures			$53.00K
YoY Change			-23.19%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			$6.186M
YoY Change			27.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			$4.800M
YoY Change			-76.21%
NET CHANGE
Cash From Operating Activities			-$12.33M
Cash From Investing Activities			$6.186M
Cash From Financing Activities			$4.800M
Net Change In Cash			-$1.341M
YoY Change			-184.71%
FREE CASH FLOW
Cash From Operating Activities			-$12.33M
Capital Expenditures			$53.00K
Free Cash Flow			-$12.38M
YoY Change			-47.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001538217
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent		usd
CY2021Q4	SRAX	Designated Assets For Return Of Capital Non Current DesignatedAssetsForReturnOfCapitalNonCurrent		usd
CY2022Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent		usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2021Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf		usd
CY2021	SRAX	Impairment Of Marketable Securities ImpairmentOfMarketableSecurities		usd
CY2021	us-gaap	Gain Loss On Sale Of Notes Receivable GainLossOnSaleOfNotesReceivable		usd
CY2021	SRAX	Gain Loss On Fair Value Of Contract Assets GainLossOnFairValueOfContractAssets		usd
CY2021	SRAX	Makewhole Provision MakewholeProvision		usd
CY2022	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax		usd
CY2022	SRAX	Loss On Disposal Of Subsidiary LossOnDisposalOfSubsidiary		usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity		usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
CY2022	SRAX	Stock Issued During Period Value Employee Options Exercised StockIssuedDuringPeriodValueEmployeeOptionsExercised		usd
CY2022	SRAX	Stock Issued During Period Value Warrants Exercised Cashless StockIssuedDuringPeriodValueWarrantsExercisedCashless		usd
CY2022	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
CY2022	SRAX	Income Loss From Discontinued Operations IncomeLossFromDiscontinuedOperations		usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf		usd
CY2021	SRAX	Impairment Of Marketable Securities ImpairmentOfMarketableSecurities		usd
CY2021	us-gaap	Gain Loss On Sale Of Notes Receivable GainLossOnSaleOfNotesReceivable		usd
CY2021	SRAX	Gain Loss On Fair Value Of Contract Assets GainLossOnFairValueOfContractAssets		usd
CY2022	SRAX	Warrants Issued For Debt WarrantsIssuedForDebt		usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2022	SRAX	Marketable Securities Received For Accounts Receivable Previously Written Off MarketableSecuritiesReceivedForAccountsReceivablePreviouslyWrittenOff		usd
CY2021	SRAX	Stock Issued For Loan Breakup Fee StockIssuedForLoanBreakupFee		usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2021	SRAX	Increase Decrease In Contracts Receivable IncreaseDecreaseInContractsReceivable		usd
CY2021	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent		usd
CY2021	SRAX	Increase Decrease In Designated Assets For Return Of Capital IncreaseDecreaseInDesignatedAssetsForReturnOfCapital		usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties		usd
CY2022	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities		usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations		usd
CY2021	us-gaap	Proceeds From Sale Of Notes Receivable ProceedsFromSaleOfNotesReceivable		usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross		usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities		usd
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations		usd
CY2021	SRAX	Proceeds From Senior Secured Revolving Facility ProceedsFromSeniorSecuredRevolvingFacility		usd
CY2021	SRAX	Repayments Of Convertiblef Notes Payable RepaymentsOfConvertiblefNotesPayable		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021	SRAX	Payments For Shares Cashless Exercise Of Employee Options Net Of Taxes Related Party PaymentsForSharesCashlessExerciseOfEmployeeOptionsNetOfTaxesRelatedParty		usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2021	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock		usd
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2022Q4	SRAX	Cash Reserved For Designated Asset For Return Of Capital CashReservedForDesignatedAssetForReturnOfCapital		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	SRAX	Debt Discount In Connection With Senior Secured Revolving Credit Facility DebtDiscountInConnectionWithSeniorSecuredRevolvingCreditFacility		usd
CY2022	us-gaap	Notes Reduction NotesReduction		usd
CY2022	SRAX	Designation Of Marketable Securities For Dividend Distributions DesignationOfMarketableSecuritiesForDividendDistributions		usd
CY2022	us-gaap	Dividends Dividends		usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2021	SRAX	Gain Loss On Fair Value Of Contract Assets GainLossOnFairValueOfContractAssets		usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent		usd
CY2022	SRAX	Marketable Securities Transfers MarketableSecuritiesTransfers		usd
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent		usd
CY2022Q4	us-gaap	Assets Designated To Closed Block Cash And Cash Equivalents AssetsDesignatedToClosedBlockCashAndCashEquivalents		usd
CY2021Q4	SRAX	Designated Assets For Return Of Capital Non Current DesignatedAssetsForReturnOfCapitalNonCurrent		usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2020Q4	SRAX	Series A Redeemable Preferred Stock SeriesARedeemablePreferredStock		usd
CY2019Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Outstanding Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageGrantDateFairValue
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2019Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Vested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingVestedWeightedAverageGrantDateFairValue
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
CY2020Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Outstanding Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageGrantDateFairValue
CY2020Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Vested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingVestedWeightedAverageGrantDateFairValue
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
CY2022	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Exercised Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageExercisedRemainingContractualTerm
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2022	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
CY2022	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Forfeited Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageForfeitedRemainingContractualTerm
CY2022	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
CY2022Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Outstanding Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageGrantDateFairValue
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Vested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingVestedWeightedAverageGrantDateFairValue
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Instrictic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedInstricticValue		usd
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodGrantDateIntrinsicValue
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2021	SRAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice		shares
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
CY2020Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Instrictic Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedInstricticValue		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022	SRAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodGrantDateIntrinsicValue
CY2022	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
CY2022Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue		usd
CY2022Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2022Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedNumberOfShares		shares
CY2022Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Nonvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingNonvestedWeightedAverageRemainingContractualTerm1
CY2022Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Instrictic Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedInstricticValue		usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2021	SRAX	Current Valuation Allowance CurrentValuationAllowance		usd
CY2021	SRAX	Deferred Valuation Allowance DeferredValuationAllowance		usd
CY2021	SRAX	Valuation Allowance Income Tax Benefit Continuing Operations ValuationAllowanceIncomeTaxBenefitContinuingOperations		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-37916
CY2022	dei	Entity Registrant Name EntityRegistrantName	SRAX, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2925231
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2629 Townsgate Road #215
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Westlake Village
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91361
CY2022	dei	City Area Code CityAreaCode	(323)
CY2022	dei	Local Phone Number LocalPhoneNumber	694-9800
CY2022	dei	Security12g Title Security12gTitle	Class A Common Stock, $0.001 par value
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	78884807	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29150262	shares
CY2022	dei	Auditor Firm AuditorFirmId	5854
CY2021	dei	Auditor Name AuditorName	RBSM LLP
CY2021	dei	Auditor Location AuditorLocation	New York, NY
CY2021	dei	Auditor Firm AuditorFirmId	587
CY2022	dei	Auditor Name AuditorName	TAAD LLP
CY2022	dei	Auditor Location AuditorLocation	Diamond Bar, CA
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1348000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	157000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	821000	usd
CY2022Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	328000	usd
CY2021Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	844000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7931000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	15617000	usd
CY2022Q4	us-gaap	Assets Designated To Closed Block Investments AssetsDesignatedToClosedBlockInvestments	100000	usd
CY2021Q4	us-gaap	Assets Designated To Closed Block Investments AssetsDesignatedToClosedBlockInvestments	3925000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	67000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	430000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8853000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	22985000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1255000	usd
CY2022Q4	SRAX	Designated Assets For Return Of Capital Non Current DesignatedAssetsForReturnOfCapitalNonCurrent	70000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	935000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	114000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1443000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	127000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	257000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	36000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	7706000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	17906000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	9217000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	20691000	usd
CY2022Q4	us-gaap	Assets Assets	18070000	usd
CY2021Q4	us-gaap	Assets Assets	43676000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7367000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12859000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1451000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	633000	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	10000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	114000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	130000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1181000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1164000	usd
CY2022Q4	SRAX	Series A Redeemable Preferred Stock SeriesARedeemablePreferredStock	994000	usd
CY2021Q4	SRAX	Series A Redeemable Preferred Stock SeriesARedeemablePreferredStock	3925000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21719000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22816000	usd
CY2022Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	5600000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	114000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5600000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	114000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	27319000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	22930000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	52718000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	51075000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61993000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-30355000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9249000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20746000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18070000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43676000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27859000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26707000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	9413000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	6521000	usd
CY2022	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	417000	usd
CY2021	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	842000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14026000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19429000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	23856000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	26792000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	4003000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-85000	usd
CY2022	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	4391000	usd
CY2021	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	10295000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	10200000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1481000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	41000	usd
CY2022	SRAX	Impairment Of Marketable Securities ImpairmentOfMarketableSecurities	3664000	usd
CY2022	us-gaap	Gain Loss On Sale Of Notes Receivable GainLossOnSaleOfNotesReceivable	-47000	usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	-8799000	usd
CY2021	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	804000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-3792000	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-7904000	usd
CY2022	SRAX	Gain Loss On Fair Value Of Contract Assets GainLossOnFairValueOfContractAssets	-1504000	usd
CY2022	SRAX	Designated Assets Realized Gain Loss DesignatedAssetsRealizedGainLoss	-1803000	usd
CY2021	SRAX	Designated Assets Realized Gain Loss DesignatedAssetsRealizedGainLoss	-84000	usd
CY2022	SRAX	Designated Assets Unrealized Gain Loss DesignatedAssetsUnrealizedGainLoss	-762000	usd
CY2021	SRAX	Designated Assets Unrealized Gain Loss DesignatedAssetsUnrealizedGainLoss	-2378000	usd
CY2022	SRAX	Gain Loss On Fair Value Of Preferred Stock GainLossOnFairValueOfPreferredStock	2566000	usd
CY2021	SRAX	Gain Loss On Fair Value Of Preferred Stock GainLossOnFairValueOfPreferredStock	2462000	usd
CY2022	SRAX	Makewhole Provision MakewholeProvision	240000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	12000	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	42000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1495000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1144000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-35641000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-16209000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31638000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16294000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-127000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-31638000	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-16167000	usd
CY2021	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-14376000	usd
CY2021	SRAX	Loss On Disposal Of Subsidiary LossOnDisposalOfSubsidiary	10684000	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-25060000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-31638000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-41227000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6465000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-31638000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-34762000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.21
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.21
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.69
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.69
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-1.06
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.06
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.75
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.75
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26247709	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26247709	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23550744	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23550744	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20746000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	-156000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-101000	usd
CY2022	SRAX	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	32000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1788000	usd
CY2022	SRAX	Stock Issued During Period Value Loan Breakup Fee StockIssuedDuringPeriodValueLoanBreakupFee	80000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-31638000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-9249000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	19225000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	19225000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1006000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	284000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5974000	usd
CY2021	SRAX	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	15952000	usd
CY2021	SRAX	Warrants Issued As Inducement To Exercise Warrants WarrantsIssuedAsInducementToExerciseWarrants	7737000	usd
CY2021	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	95000	usd
CY2021	SRAX	Noncontrolling Interest Increase From Warrants Issued NoncontrollingInterestIncreaseFromWarrantsIssued	885000	usd
CY2021	SRAX	Noncontrolling Interest Series B Convertible Preferred Stock Issued NoncontrollingInterestSeriesBConvertiblePreferredStockIssued	5860000	usd
CY2021	SRAX	Noncontrolling Interest Increase From Convertible Debt With Conversion Feature NoncontrollingInterestIncreaseFromConvertibleDebtWithConversionFeature	5860000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	6387000	usd
CY2021	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	6465000	usd
CY2021	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	-793000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-34762000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6465000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20746000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20746000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-31638000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-41227000	usd
CY2021	SRAX	Income Loss From Discontinued Operations IncomeLossFromDiscontinuedOperations	25060000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-31638000	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-16167000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	10200000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1481000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	41000	usd
CY2022	SRAX	Impairment Of Marketable Securities ImpairmentOfMarketableSecurities	3664000	usd
CY2022	us-gaap	Gain Loss On Sale Of Notes Receivable GainLossOnSaleOfNotesReceivable	-47000	usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-8799000	usd
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	804000	usd
CY2022	SRAX	Unrealized Gain Loss On Marketable Securities UnrealizedGainLossOnMarketableSecurities	-6020000	usd
CY2021	SRAX	Unrealized Gain Loss On Marketable Securities UnrealizedGainLossOnMarketableSecurities	-7904000	usd
CY2022	SRAX	Gain Loss On Fair Value Of Contract Assets GainLossOnFairValueOfContractAssets	-1504000	usd
CY2022	SRAX	Designated Assets Realized Gain Loss DesignatedAssetsRealizedGainLoss	-1803000	usd
CY2021	SRAX	Designated Assets Realized Gain Loss DesignatedAssetsRealizedGainLoss	-84000	usd
CY2022	SRAX	Designated Assets Unrealized Gain Loss DesignatedAssetsUnrealizedGainLoss	-762000	usd
CY2021	SRAX	Designated Assets Unrealized Gain Loss DesignatedAssetsUnrealizedGainLoss	-2378000	usd
CY2022	SRAX	Gain Loss On Fair Value Of Preferred Stock GainLossOnFairValueOfPreferredStock	2566000	usd
CY2021	SRAX	Gain Loss On Fair Value Of Preferred Stock GainLossOnFairValueOfPreferredStock	2462000	usd
CY2022	SRAX	Forgiveness Of Payroll Protection Program Loan ForgivenessOfPayrollProtectionProgramLoan	-10000	usd
CY2021	SRAX	Forgiveness Of Payroll Protection Program Loan ForgivenessOfPayrollProtectionProgramLoan	-1116000	usd
CY2021	SRAX	Warrants Issued For Debt WarrantsIssuedForDebt	885000	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	7737000	usd
CY2021	SRAX	Marketable Securities Received For Accounts Receivable Previously Written Off MarketableSecuritiesReceivedForAccountsReceivablePreviouslyWrittenOff	409000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	130000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	163000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	218000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	854000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	-156000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1006000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	119000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-20000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	417000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	919000	usd
CY2022	SRAX	Interest Expense Incurred In Connection With Noncash Increase Of Debt InterestExpenseIncurredInConnectionWithNoncashIncreaseOfDebt	165000	usd
CY2021	SRAX	Interest Expense Incurred In Connection With Noncash Increase Of Debt InterestExpenseIncurredInConnectionWithNoncashIncreaseOfDebt	268000	usd
CY2022	SRAX	Stock Issued For Loan Breakup Fee StockIssuedForLoanBreakupFee	80000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1788000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-545000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1680000	usd
CY2022	SRAX	Increase Decrease In Contracts Receivable IncreaseDecreaseInContractsReceivable	988000	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	263000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-399000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	820000	usd
CY2022	SRAX	Increase Decrease In Designated Assets For Return Of Capital IncreaseDecreaseInDesignatedAssetsForReturnOfCapital	-684000	usd
CY2022	SRAX	Increase Decrease In Note Receivable IncreaseDecreaseInNoteReceivable	12000	usd
CY2021	SRAX	Increase Decrease In Note Receivable IncreaseDecreaseInNoteReceivable	42000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	6358000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	3278000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	159000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-22765000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-20669000	usd
CY2021	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-131000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	818000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	350000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-130000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-183000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12327000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15317000	usd
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-8118000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12327000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23435000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	5221000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	8666000	usd
CY2022	SRAX	Proceeds From Sale Of Designated Assets ProceedsFromSaleOfDesignatedAssets	506000	usd
CY2021	SRAX	Proceeds From Sale Of Designated Assets ProceedsFromSaleOfDesignatedAssets	686000	usd
CY2022	us-gaap	Proceeds From Sale Of Notes Receivable ProceedsFromSaleOfNotesReceivable	900000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1450000	usd
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	3004000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	53000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	69000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	388000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	798000	usd
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	33000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	6186000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3998000	usd
CY2021	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	841000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6186000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4839000	usd
CY2022	SRAX	Proceeds From Senior Secured Revolving Facility ProceedsFromSeniorSecuredRevolvingFacility	5450000	usd
CY2022	SRAX	Repayments Of Convertiblef Notes Payable RepaymentsOfConvertiblefNotesPayable	216000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	284000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	32000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	15952000	usd
CY2022	SRAX	Payments For Shares Cashless Exercise Of Employee Options Net Of Taxes Related Party PaymentsForSharesCashlessExerciseOfEmployeeOptionsNetOfTaxesRelatedParty	101000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	793000	usd
CY2022	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	365000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4800000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	15443000	usd
CY2021	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	4736000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4800000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20179000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1341000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1583000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1348000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	451000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	7000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2034000	usd
CY2021Q4	SRAX	Cash Reserved For Designated Asset For Return Of Capital CashReservedForDesignatedAssetForReturnOfCapital	-686000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1348000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	222326	usd
CY2022	SRAX	Marketable Securities Received In Exchange For Accounts Receivable MarketableSecuritiesReceivedInExchangeForAccountsReceivable	17273000	usd
CY2021	SRAX	Marketable Securities Received In Exchange For Accounts Receivable MarketableSecuritiesReceivedInExchangeForAccountsReceivable	27842000	usd
CY2022	SRAX	Debt Discount In Connection With Senior Secured Revolving Credit Facility DebtDiscountInConnectionWithSeniorSecuredRevolvingCreditFacility	750000	usd
CY2021	us-gaap	Notes Reduction NotesReduction	5974000	usd
CY2021	SRAX	Designation Of Marketable Securities For Dividend Distributions DesignationOfMarketableSecuritiesForDividendDistributions	6387000	usd
CY2021	us-gaap	Dividends Dividends	6387000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80F_eus-gaap--NatureOfOperations_zsjz7lWUrmS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Note 1 - <span id="xdx_829_za72L5hjsigi">Organization and Nature of Operations</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SRAX, Inc. (“SRAX,” “we,” “us,” “our” or the “Company”) is a Delaware corporation formed on August 2, 2011. SRAX is headquartered in Westlake Village, California but operates as a distributed virtual Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the Consolidated Financial Statements consist of SRAX and its wholly owned subsidiary LD Micro, Inc. (“LD Micro”, “LD Micro, Inc.” or “LDMI”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature of Operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SRAX is a technology firm focused on enhancing communications between public companies and their shareholders and investors. The Company currently has one reportable and operating segment, which consists of one reporting unit consisting of two distinct business units.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of SRAX’s business units deliver valuable insights that assist our clients with their investor relations and communications initiatives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Sequire</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unique SaaS platform, Sequire, provides users many features which allow issuers to track their shareholders’ behaviors and trends, then use data-driven insights to engage with shareholders across marketing channels.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">LD Micro</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through LD Micro, Inc. (“LD”), the Company organizes and hosts investor conferences within the micro and small cap markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to year end, on March 3, 2023, the Company divested LD through a sale and will account for this as a deconsolidation and gain on disposal. See Note 22.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 12pt Cambria, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SRAX, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 12pt Cambria, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 12pt Cambria, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER 31, 2022 AND 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Force Protection Video Equipment Corporation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 4, 2021, the Company acquired FPVD through a reverse acquisition involving BIG Token, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">BIG Token, Inc. (“BIGToken”)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 29, 2021, we deconsolidated our majority owned subsidiary BIG Token, Inc. (“BIGToken”) (formerly known as Force Protection Video Equipment Corporation). After the deconsolidation, we did not beneficially own a controlling interest in BIGToken, and no longer consolidated BIGToken into our financial results for periods ending after December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial results of BIGToken for the year ended December 31, 2021 are presented as income from discontinued operations, net of taxes on the consolidated statements of operations and its assets and liabilities as of December 31, 2021 are presented as assets and liabilities of discontinued operations on the consolidated balance sheets. The historical consolidated statement of cash flows reflects the effect of the deconsolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless noted otherwise, discussion in the notes to the consolidated financial statements pertain to continuing operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 4 – Discontinued Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 20 - Warrants</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation and Rounding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amounts in the accompanying consolidated financial statements and notes are presented in thousands (except per share amounts), unless otherwise stated. As a result, certain totals may not sum due to rounding.</span></p>
CY2022	us-gaap	Profit Loss ProfitLoss	-31638000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12327000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61993000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-9249000	usd
CY2022Q4	SRAX	Working Capital Deficit WorkingCapitalDeficit	-12866000	usd
CY2022Q4	us-gaap	Cash Cash	7000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	10200000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	7706000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	17906000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zpz1v1xxxIA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z0fiwez1kFP6">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates during the years ended December 31, 2022 and 2021, respectively, include:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">revenue recognition (receipt of marketable securities for services to be rendered at fair value),</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">valuation of marketable securities (including impairment losses), using a third party independent valuation expert,</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allowance for doubtful accounts and other receivables,</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">valuation of loss contingencies,</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">valuation of goodwill and intangibles and related impairments,</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">valuation of stock-based compensation (common and preferred stock, stock options and warrants),</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">estimated useful lives related to intangible assets and related impairments (including goodwill),</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">estimated useful lives related to property and equipment and related impairments,</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implicit interest rate in right-of-use operating leases,</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertain tax positions; and</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">valuation allowance on deferred tax assets.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1098000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	271000	usd
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	951000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	114000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	130000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	157000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	821000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	119000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-20000	usd
CY2022	SRAX	Gain Loss On Fair Value Of Contract Assets GainLossOnFairValueOfContractAssets	-1504000	usd
CY2022Q4	us-gaap	Contract With Customer Receivable Allowance For Credit Loss ContractWithCustomerReceivableAllowanceForCreditLoss	0	usd
CY2021Q4	us-gaap	Contract With Customer Receivable Allowance For Credit Loss ContractWithCustomerReceivableAllowanceForCreditLoss	0	usd
CY2022	us-gaap	Contract With Customer Receivable Credit Loss Expense Reversal ContractWithCustomerReceivableCreditLossExpenseReversal	0	usd
CY2021	us-gaap	Contract With Customer Receivable Credit Loss Expense Reversal ContractWithCustomerReceivableCreditLossExpenseReversal	0	usd
CY2022Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	328000	usd
CY2021Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	844000	usd
CY2022	SRAX	Impairment Of Marketable Securities ImpairmentOfMarketableSecurities	3664000	usd
CY2022Q4	SRAX	Marketable Securities Other Than Temporary Losses MarketableSecuritiesOtherThanTemporaryLosses	0	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	9186000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	15617000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	10200000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1481000	usd
CY2022	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	<p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentImpairment_z999fDxYJbi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zEffZmCerbO3">Property and Equipment and Related Impairment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided on the straight-line basis over the estimated useful lives of the assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management reviews the carrying value of its property and equipment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 12pt Cambria, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SRAX, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 12pt Cambria, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 12pt Cambria, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER 31, 2022 AND 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment loss for the years ended December 31, 2022 and 2021, were $<span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_c20220101__20221231_za0PqHOzgq9d" title="Impairment loss">41,000</span> and $<span id="xdx_905_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_dxL_c20210101__20211231_zFwxI0MNHTVg" title="Impairment loss on property and equipment::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1024">0</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	41000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
CY2022Q4	SRAX	Series A Redeemable Preferred Stock SeriesARedeemablePreferredStock	994000	usd
CY2021Q4	SRAX	Series A Redeemable Preferred Stock SeriesARedeemablePreferredStock	3925000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7367000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12859000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	83000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	225000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3486720	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10589877	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q2	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	497000	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zZSnoOR8gGj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zheL48uHHf02">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no material effect on the consolidated results of operations, stockholders’ deficit, or cash flows.</span></p>
CY2020Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	468000	usd
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	0	usd
CY2021Q4	us-gaap	Line Of Credit LineOfCredit	631000	usd
CY2020Q4	us-gaap	Proceeds From Sale Of Notes Receivable ProceedsFromSaleOfNotesReceivable	8000000	usd
CY2020Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	7000000	usd
CY2020Q4	SRAX	Additional Repurchase Of Notes Receivable AdditionalRepurchaseOfNotesReceivable	1000000	usd
CY2020Q4	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	1000000	usd
CY2020Q4	us-gaap	Receivable With Imputed Interest Discount ReceivableWithImputedInterestDiscount	107000	usd
CY2020Q4	SRAX	Notes Receivable Amortized Period NotesReceivableAmortizedPeriod	amortized over 3 years.
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	947000	usd
CY2022	us-gaap	Proceeds From Sale Of Notes Receivable ProceedsFromSaleOfNotesReceivable	900000	usd
CY2022	us-gaap	Gain Loss On Sale Of Notes Receivable GainLossOnSaleOfNotesReceivable	-47000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	935000	usd
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	8447000	usd
CY2021	SRAX	Marketable Securities Addition MarketableSecuritiesAddition	34914000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	8666000	usd
CY2021	SRAX	Marketable Securities Designationfor Dividend Distribution MarketableSecuritiesDesignationforDividendDistribution	10790000	usd
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	8288000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	15617000	usd
CY2022	SRAX	Marketable Securities Addition MarketableSecuritiesAddition	17273000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	5221000	usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	-8799000	usd
CY2022	SRAX	Marketable Securities Impairments MarketableSecuritiesImpairments	3664000	usd
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	6020000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	9186000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7931000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	15617000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1255000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	9186000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	15617000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	5221000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	8666000	usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	-8799000	usd
CY2021	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	804000	usd
CY2022Q4	us-gaap	Assets Designated To Closed Block Equity Securities At Fair Value AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue	170000	usd
CY2021Q4	us-gaap	Assets Designated To Closed Block Equity Securities At Fair Value AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue	3239000	usd
CY2021Q4	us-gaap	Assets Designated To Closed Block Cash And Cash Equivalents AssetsDesignatedToClosedBlockCashAndCashEquivalents	686000	usd
CY2022Q4	us-gaap	Assets Designated To Closed Block AssetsDesignatedToClosedBlock	170000	usd
CY2021Q4	us-gaap	Assets Designated To Closed Block AssetsDesignatedToClosedBlock	3925000	usd
CY2022Q4	us-gaap	Assets Designated To Closed Block Investments AssetsDesignatedToClosedBlockInvestments	100000	usd
CY2021Q4	us-gaap	Assets Designated To Closed Block Investments AssetsDesignatedToClosedBlockInvestments	3925000	usd
CY2022Q4	SRAX	Designated Assets For Return Of Capital Non Current DesignatedAssetsForReturnOfCapitalNonCurrent	70000	usd
CY2022Q4	us-gaap	Assets Designated To Closed Block AssetsDesignatedToClosedBlock	170000	usd
CY2021Q4	us-gaap	Assets Designated To Closed Block AssetsDesignatedToClosedBlock	3925000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	320000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	357000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	114000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	41000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	417000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	842000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5970000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-4527000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1443000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	350000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	919000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1481000	usd
CY2022Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	5580000	usd
CY2022Q4	us-gaap	Share Price SharePrice	2.42
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1216000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	6200000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	7416000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	9684000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	994000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	20386000	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3925000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	127000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	257000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	114000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	244000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.18	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.18	pure
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	130000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	163000	usd
CY2022	SRAX	Lease Liability Expense In Connection With Obligation Repayment LeaseLiabilityExpenseInConnectionWithObligationRepayment	33000	usd
CY2021	SRAX	Lease Liability Expense In Connection With Obligation Repayment LeaseLiabilityExpenseInConnectionWithObligationRepayment	12000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	163000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	175000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	123000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	123000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	114000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	114000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7476000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1938000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2540000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1731000	usd
CY2022Q4	SRAX	Accruedinterest Payable AccruedinterestPayable	424000	usd
CY2021Q4	SRAX	Accruedinterest Payable AccruedinterestPayable	123000	usd
CY2022Q4	SRAX	Accrued Commissions Current AccruedCommissionsCurrent	13000	usd
CY2021Q4	SRAX	Accrued Commissions Current AccruedCommissionsCurrent	303000	usd
CY2022Q4	SRAX	Accounts Payable And Accrued Liabilities AccountsPayableAndAccruedLiabilities	10453000	usd
CY2021Q4	SRAX	Accounts Payable And Accrued Liabilities AccountsPayableAndAccruedLiabilities	4095000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1451000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	633000	usd
CY2022	SRAX	Forgiveness Of Payroll Protection Program Loan ForgivenessOfPayrollProtectionProgramLoan	-10000	usd
CY2021	SRAX	Forgiveness Of Payroll Protection Program Loan ForgivenessOfPayrollProtectionProgramLoan	-1116000	usd
CY2021	SRAX	Dividends On Redeemable Preferred Stock DividendsOnRedeemablePreferredStock	6387000	usd
CY2021	SRAX	Dividends On Preferred Stock DividendsOnPreferredStock	-2462000	usd
CY2021Q4	SRAX	Series A Redeemable Preferred Stock SeriesARedeemablePreferredStock	3925000	usd
CY2022	SRAX	Dividends On Preferred Stock DividendsOnPreferredStock	-2566000	usd
CY2022	SRAX	Payments For Series Preferred Stock Distribution PaymentsForSeriesPreferredStockDistribution	365000	usd
CY2022Q4	SRAX	Series A Redeemable Preferred Stock SeriesARedeemablePreferredStock	994000	usd
CY2022	SRAX	Proceeds From Warrant Exercise ProceedsFromWarrantExercise	32000	usd
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	3.75
CY2022	SRAX	Stock Issued During Period Value Loan Breakup Fee StockIssuedDuringPeriodValueLoanBreakupFee	80000	usd
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.67
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	6828611	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	7148501	shares
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	15952000	usd
CY2021Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.33
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1642324	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.30
CY2020	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P2Y9M21D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	844742	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.54
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P2Y7M13D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	333000	usd
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	797582	shares
CY2019Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice	2.81
CY2020	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding N Onvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingNOnvestedWeightedAverageRemainingContractualTerm1	P3Y
CY2019Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Instrictic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedInstricticValue	207000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	21627	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.38
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm	P6Y3M14D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.60
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	12500	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.70
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Exercised Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageExercisedRemainingContractualTerm	P3Y7M17D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	317164	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.60
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Forfeited Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageForfeitedRemainingContractualTerm	P0Y7M24D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1334287	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.02
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P2Y4M20D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1969000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	870750	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.05
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P2Y3M7D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1265000	usd
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	461030	shares
CY2020Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice	2.96
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding N Onvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingNOnvestedWeightedAverageRemainingContractualTerm1	P2Y7M13D
CY2020Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Instrictic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedInstricticValue	703000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	718132	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.27
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.72
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	427667	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.21
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	266333	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.28
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1358419	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.57
CY2022	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P3Y11M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	798502	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.41
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y9M25D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	559917	shares
CY2022Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice	3.79
CY2022	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding N Onvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingNOnvestedWeightedAverageRemainingContractualTerm1	P4Y1M17D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.90	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0	pure
CY2022	SRAX	Reversed Stock Based Compensation ReversedStockBasedCompensation	1139000	usd
CY2022Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vesting Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestingExercisableAggregateIntrinsicValue	983000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	-156000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1006000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1333000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M28D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	12585283	shares
CY2019Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	2.98
CY2020	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1	P1Y9M10D
CY2019Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	4460000	usd
CY2019Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestOutstandingNumber	12285283	shares
CY2019Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.94
CY2020	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P1Y8M26D
CY2019Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	4460000	usd
CY2019Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedNumberOfShares	300000	shares
CY2019Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedWeightedAverageGrantDateFairValue	4.75
CY2020	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Nonvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingNonvestedWeightedAverageRemainingContractualTerm1	P3Y4M13D
CY2019Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Instrictic Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedInstricticValue	-0	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	4582345	shares
CY2021	SRAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice	7.48
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm	P0Y1M9D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	7148501	shares
CY2021	SRAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice	2.74
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Exercised Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageExercisedRemainingContractualTerm	P0Y9M10D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	10019127	shares
CY2020Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	5.21
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1	P0Y5M19D
CY2020Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	6779000	usd
CY2020Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestOutstandingNumber	9719127	shares
CY2020Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.22
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P0Y4M28D
CY2020Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	6779000	usd
CY2020Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedNumberOfShares	300000	shares
CY2020Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedWeightedAverageGrantDateFairValue	4.75
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Nonvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingNonvestedWeightedAverageRemainingContractualTerm1	P2Y4M13D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	697574	shares
CY2022	SRAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice	3.09
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	6633335	shares
CY2022	SRAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.50	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2688218	shares
CY2022Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	2.82
CY2022	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1	P0Y7M20D
CY2022Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestOutstandingNumber	2688218	shares
CY2022Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.82
CY2022	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P0Y7M20D
CY2021Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4930000	usd
CY2021Q1	SRAX	Number Of Warrants Cancelled NumberOfWarrantsCancelled	349197	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2283171	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	6828611	shares
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	15952000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13739000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10003000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	29000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	33000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	683000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	525000	usd
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	161000	usd
CY2022Q4	SRAX	Deferred Tax Assets Contribution Carryover DeferredTaxAssetsContributionCarryover	5000	usd
CY2021Q4	SRAX	Deferred Tax Assets Contribution Carryover DeferredTaxAssetsContributionCarryover	5000	usd
CY2022Q4	SRAX	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	29000	usd
CY2021Q4	SRAX	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	62000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Availablefor Sale Securities Gross DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross	2445000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Availablefor Sale Securities Gross DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross	2668000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	124000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16953000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	13581000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	15000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	29000	usd
CY2022Q4	SRAX	Deferred Tax Liabilities Rightofuse Asset DeferredTaxLiabilitiesRightofuseAsset	33000	usd
CY2021Q4	SRAX	Deferred Tax Liabilities Rightofuse Asset DeferredTaxLiabilitiesRightofuseAsset	66000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	151000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	455000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	15000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	15000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	214000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	565000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	16719000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	13016000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16719000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13016000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3239000	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-3239000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-667000	usd
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-661000	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	6000	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-3906200	usd
CY2022	SRAX	Federal State And Local Tax Expense Benefit Continuing Operations FederalStateAndLocalTaxExpenseBenefitContinuingOperations	-3900000	usd
CY2022	SRAX	Current Valuation Allowance CurrentValuationAllowance	-6000	usd
CY2022	SRAX	Deferred Valuation Allowance DeferredValuationAllowance	3906200	usd
CY2022	SRAX	Valuation Allowance Income Tax Benefit Continuing Operations ValuationAllowanceIncomeTaxBenefitContinuingOperations	3900000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-132000	usd
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-132000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	usd
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	5000	usd
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	5000	usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-132000	usd
CY2021	SRAX	Federal State And Local Tax Expense Benefit Continuing Operations FederalStateAndLocalTaxExpenseBenefitContinuingOperations	-127000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-132000	usd
CY2021	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	-127000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.068	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.000	pure
CY2022	SRAX	Effective Income Tax Rate Reconciliation Preferred Tax Liability Remeasurement EffectiveIncomeTaxRateReconciliationPreferredTaxLiabilityRemeasurement	0.017	pure
CY2021	SRAX	Effective Income Tax Rate Reconciliation Preferred Tax Liability Remeasurement EffectiveIncomeTaxRateReconciliationPreferredTaxLiabilityRemeasurement	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.003	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.010	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.123	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.151	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.033	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.041	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.008	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	50106000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	The Company is in the process of analyzing its NOL and has not determined if the company has had any change of control issues that could limit the future use of NOL. Additionally, the Company is in the process of filing its 2020 through 2022 tax returns. NOL carryforwards that were generated after 2017 of approximately $39,600,000 may only be used to offset 80% of taxable income and are carried forward indefinitely.
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	39600000	usd

Files In Submission

Name	View Source	Status
0001493152-24-037704-index-headers.html	Edgar Link	pending
0001493152-24-037704-index.html	Edgar Link	pending
0001493152-24-037704.txt	Edgar Link	pending
0001493152-24-037704-xbrl.zip	Edgar Link	pending
aud_001.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
logo_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
srax-20221231.xsd	Edgar Link	pending
srax-20221231_lab.xml	Edgar Link	unprocessable
srax-20221231_pre.xml	Edgar Link	unprocessable
srax-20221231_cal.xml	Edgar Link	unprocessable
srax-20221231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SRAX
SRAX, Inc. Stock $srax

2024 Q3 Form 10-K Financial Statement

#000149315224037704 Filed on September 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SRAX SRAX, Inc. Stock $srax

2024 Q3 Form 10-K Financial Statement

#000149315224037704 Filed on September 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SRAX
SRAX, Inc. Stock $srax